Mycoplasma is eluded to as the class of bacteria often exist in cell culture. It is also called mollicutes, these bacteria require a cell wall, which makes them resistant to frequently use antibiotics, like penicillin. Mycoplasma is spreadable via droplets throughout cell culture and can be persistent in dried form for months. Mycoplasma infection is complicated to see with a microscope and involves specific testing, to get identified. Mycoplasma organisms can affect cell growth, tumorigenicity, metabolism, and response to therapy.
According to the report analysis,’ Global Mycoplasma Testing Market is valued approximately USD 662 million in 2019 and is anticipated to grow with a healthy growth rate of more than 12.5% over the forecast period 2020-2026’ states that rising analysis activities conducted by pharmaceutical and biotechnology firms raised government support and funding in research activities and growing cell culture contamination around the globe are the few factors responsible for the high expansion of the market during the forecast amount. For instance, in 2018, Boehringer Ingelheim, a pharmaceutical company, has announced its plans to invest almost USD 259 million for its novel Biologicals Development Center (BDC), to be cited as an R&D hub in Germany. Similarly, Merck KGaA is also working on a plan to invest around USD 16 billion in R&D over the next five years, additionally its yearly investment of USD 7 billion. Thus, a large amount of investments in R&D activities is predicted to propel the demand for mycoplasma testing products around the globe. Although, a high degree of consolidation acts and a rigorous regulatory framework are the few factors expected to hinder the expansion of the market during the forecast amount.
Key market players include Charles River Laboratories International, Inc., Merck KGaA, Lonza Group Ltd., Roche Diagnostics (Division of F. Hoffman-La Roche Ltd.), Biounique Testing Laboratories Inc., Invivogen, Promocell GmbH, Thermo Fisher Scientific Inc., American Type Culture Collection, and Biological Industries Israel Beit Haemek Ltd. The major ways adopted by these corporates include mergers and acquisitions, new product launch, and geographical growth. The detailed segments and sub-segment of the market are as follows: By Product & Services into Reagents & Kits, Instruments and Services & Software. By Technique into Polymerase Chain Reaction (PCR), Elisa, Direct Assays, Indirect Assays, DNA Staining, and Others. By Application into Cell Line Testing, Virus Testing, End-of-Production Cell Testing, and Others. By End-User into Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, Cell Banks, and Others.
Furthermore, increasing investments in R&D activities have contributed to a very large revenue for the market. The rising introduction of novel technologies by key players is anticipated to additional boost growth. The rise in cell culture contamination is additionally another issue driving growth. Because of the restriction of culture methods, researchers are concerned with the identification and development of more quick and exact mycoplasma tests in recent years. The primary advantages of such rapid tests would be high sensitivity, the ability to detect a high range of mycoplasma species, and multiplying time reduction, thus, reducing the production time. These rapid methods would conjointly facilitate faster decision making to reduce the spread of contamination. Increasing research activities conducted by pharmaceutical and biotechnology firms are leading to the adoption of new technologies for drug discovery and development. Thus, an enormous amount of spending in R&D activities is anticipated to drive developments in this field, thereby boosting the demand for mycoplasma testing products throughout the forecast amount.
For More Information on the Research Report, refer to below links: -
Ankur Gupta, Head Marketing & Communications